The World Anti-Doping Agency´s 2009 Prohibited List will come into force on the 1st of January 2009. The Prohibited List 2009 is found here and the Summary of Modifications are found here. More information also found on WADA´s webpage www.wada-ama.org and the Questions and Answers on the WADA Code Revisions are found here.
IFF new Anti-Doping Regulations
The IFF Anti-Doping Regulations (approved by WADA in October 2008 and IFF General Assembly December 13th) will come into effect on January 1st 2009 (Prohibited List and sanctions concerning Anti-doping rule violations) with a transfer period until 1st of April (Testing Pools, Whereabouts).
The new IFF Anti-Doping Regulations 2009 are published under Rules & Regulations and more relevant information will also be added to the IFF webpage under Anti-Doping in the beginning of 2009.
THE MAJOR CHANGES IN THE PROHIBITED LIST 2009
· Alpha-reductase inhibators
A class of masking agents which used to be banned, are removed from the 2009 List. This class of substances includes for example Finasteride (for hair loss)
· Asthma medication:
A. Beta-2 Agonists
The Abbreviated TUEs (ATUEs) have been removed. Inhaled formoterol, salbutalmol, salmeterol, and terbutaline require a Therapeutic Use Exemption in accordance with the new International Standard for Therapeutic Use Exemptions (found on www.wada-ama.org under International Standards).
This means that there are minimal requirements to be attached with the TUE when using Beta-2 Agonists:
1. A complete medical history
2. A comprehensive report of the clinical examinations with specific focus on the respiratory system
3. A report of spirometry with the measure of the Forced Expiratory Volume in 1 second (FEV1)
4. If airway obstruction is present, the spirometry will be repeated after inhalation of a short acting Beta2 agonist to demonstrate the reversibility of bronchocontriction.
5. In the absence of reversible airway obstruction, a bronchial provocation test is required to establish the presence of airway-hyper responsiveness.
6. Exact name, speciality, address (including telephone, e-mail, fax) of examining physician
B. Glucocorticosteroids:
· A Declaration of Use Process must be completed by the Athlete for the administration of glucocorticosteroids by intraarticular, periarticular, perintendinous, epidural, intradermal and inhalation routes (cortisone injections and inhaled asthma medication with cortisone).
· No TUE or declaration of use is required for topical administration of glucocorticosteroids.
The “old” already approved Abbreviated Therapeutic Use Exemptions (ATUEs) delivered prior to December 31, 2008 shall remain valid after January 1, 2009 until the earliest of:
(i) The date on which they are cancelled by the competent TUEC following review in accordance with art. 8.6 of the 2005 TUE Standard;
(ii) Their expiry date as mentioned on the ATUE;
(iii) December 31, 2009
More information about TUE´s found in the WADA´s International Standard for Therapeutic Use Exemptions
More information about Testing found in the WADA´s International Standard for Testing
